© 2020 All Rights Reserved. Katan Associates International.

  • LinkedIn - Grey Circle
  • Twitter - Grey Circle
  • Facebook - Grey Circle

Mar 20, 2018

Kalytera Initiates Program to Develop a Novel Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera”) today announced that it is has begun development of a novel cannabinoid-based compound for the treatment of acute and chronic pain. Patents for this compound have been filed in the U.S. and other jurisdictions, and Kalytera has obtained an exclusive, worldwide license for this compound from Beetlebung Pharma, Ltd., an Israeli-based pharmaceutical discovery company focused on cannabinoid-based therapeutics for the treatment of human disease (“BPL”). https://kalytera.co/news/cannabinoid-based-compound-for-acute-and-chronic-pain-program-initiation/

Jan 31, 2018

Kalytera Announces Grant of Stock Options

Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (KALTF) (the “Company” or “Kalytera”) today announced that it has granted stock options on January 30, 2018 to certain directors and officers of the Company. The stock options have an exercise price of $0.38 per common share and expire ten years from the date of grant. https://kalytera.co/news/grant-of-stock-options/

Jan 26, 2018

Kalytera Announces Issuance of Shares under Services Agreement with The Salzman Group of Israel

Kalytera Therapeutics, Inc. (KALY.V) (KALTF) (the “Company” or “Kalytera”) today announced that the Company has elected to issue 396,015 common shares of the Company (“Common Shares”) to The Salzman Group in payment of an invoice issued under the services agreement with The Salzman Group previously announced on December 7, 2017 (the “Agreement”). Under the Agreement, The Salzman Group provides, among other services, clinical study management services in relation to the Phase 2 study evaluating the use of cannabidiol in the prevention of graft versus host disease. https://kalytera.co/news/issuance-of-shares-under-services-agreement-with-the-salzman-group-of-israel/

Jan 11, 2018

Kalytera Announces Settlement of Debt Transactionces Approval of Shares for Services and Settlement of Debt Transaction with The Salzman Group of Israel

Kalytera Therapeutics, Inc. (KALY.V) (KALTF) (the “Company” or “Kalytera”) today announced that it has entered into an agreement to pay amounts owing to a service provider for past services in common shares of the Company (“Common Shares”). The transaction is subject to approval by the TSX Venture Exchange (“TSXV”). https://kalytera.co/investors/news-archive/?2018

Dec 22, 2017

Kalytera Announces Approval of Shares for Services and Settlement of Debt Transaction with The Salzman Group of Israel

Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (KALTF) (the “Company” or “Kalytera”) today announced that the TSX Venture Exchange (“TSXV”) has approved the arrangement reached with The Salzman Group of Israel to allow Kalytera, at its option, to pay invoices under a services agreement with The Salzman Group in common shares of the Company (“Common Shares”). As previously announced on December 7, 2017, Kalytera has entered into a services agreement with The Salzman Group (the “Agreement”), under which The Salzman Group will provide clinical study management services in relation to the Phase 2 study, including chemistry, manufacturing and controls (“CMC”) analytics, as well as stability studies, toxicology studies and drug-drug interaction studies, all of which will be required by the FDA to be completed prior to initiation of a Phase 3 pivotal study. https://kalytera.co/news/kalytera-announces-approval-of-shares-for-services-and-settlement-of-debt-transaction-with-the-salzman-group-of-israel/

Dec 20, 2017

Kalytera Announces Closing of Brokered Private Placement

Kalytera Therapeutics, Inc. (TSX Venture: KALY) (OTCQB:KALTF) (the “Company” or “Kalytera”) is pleased to announce the closing of its previously announced brokered private placement offering (the “Offering”) of CDN$5,750,000 aggregate principal amount of convertible debenture units at a price of CDN$1,000 per convertible debenture unit, which includes the full exercise by the Echelon Wealth Partners Inc. (“Echelon”) of its option to sell an additional 750 convertible debenture units. Echelon acted as agent for and on behalf of the Company in connection with the Offering. The net proceeds of the Offering will be used by the Company to advance its Phase 2 clinical program evaluating the use of cannibidiol in the prevention of graft versus host disease, as well as for general corporate purposes. https://kalytera.co/news/kalytera-announces-closing-of-brokered-private-placement/ 

Dec 07, 2017

Kalytera Announces Initiation of Phase 2 Clinical Study in Prevention of Graft Versus Host Disease and Agreement with The Salzman Group of Israel to Manage and Partially Fund the Study to be Led by a World Class Team

Kalytera Therapeutics, Inc. (TSX-V:KALY) and (OTCQB:KALTF) (the “Company” or “Kalytera”) today announced the initiation of a Phase 2 clinical study evaluating the use of cannabidiol (“CBD”) in the prevention of graft versus host disease (“GVHD”). Kalytera also announced today that it has entered into an agreement with The Salzman Group of Israel, under which The Salzman Group will, among other things, accept common shares of Kalytera in payment for its services in connection with the Phase 2 study, subject to TSX Venture Exchange approval. https://kalytera.co/news/initiation-of-phase-2-clinical-study-in-prevention-of-gvhd-and-agreement-with-the-salzman-group/

Dec 05, 2017

Kalytera Confirms No Material Change in Operations

At the request of IIROC, Kalytera Therapeutics, Inc. (TSX-V:KALY) (OTCQB:KALTF) (the “Company” or “Kalytera“) wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity. https://kalytera.co/news/kalytera-confirms-no-material-change-in-operations/

Nov 27, 2017

Kalytera Announces Second US Patent for Prevention and Treatment of Graft Versus Host Disease

Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for a second patent covering the use of cannabidiol (“CBD”) in the prevention and treatment of graft versus host disease (“GVHD”). https://kalytera.co/news/second-us-patent-for-prevention-and-treatment-of-gvhd/

Nov 22, 2017

Kalytera Announces $5 Million Private Placement of Convertible Debenture Units

Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (KALTF) (the “Company” or “Kalytera”) announced today that it has entered into an agreement with Echelon Wealth Partners Inc. (“Echelon” or the “Agent”), to lead a brokered best efforts private placement of up to $5,000,000 aggregate principal amount of convertible debenture units (the “Convertible Debenture Units”) at a price of $1,000 per Convertible Debenture Unit (the “Offering”). Each Convertible Debenture Unit will consist of: (i) $1,000 principal amount of 9.0% secured convertible debentures (the “Convertible Debentures”); and (ii) 3,846 common share purchase warrants (each whole warrant, a “Warrant”) of the Company (representing 50% warrant coverage on each Convertible Debenture). https://kalytera.co/news/kalytera-announces-5-million-private-placement-of-convertible-debenture-units/

Nov 15, 2017

Kalytera Announces Notice of Allowance of US Patent for Treatment of Graft Versus Host Diseaseounces Robert Farrell, J.D. as CEO; Additional Board and Management Changes

Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance for US Patent Application 15/143,694 covering the use of cannabidiol (“CBD”) in the treatment of graft versus host disease (“GVHD”). Securing a patent for this proprietary technology represents an important step forward for the Company in its work focused on the treatment of this serious and life-threatening disease. https://kalytera.co/news/gvhd-us-patent-allowance/

Oct 10, 2017

Kalytera Announces Robert Farrell, J.D. as CEO; Additional Board and Management Changes

Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce that Robert Farrell, J.D., has been appointed as the Company’s Chief Executive Officer (“CEO”). Mr. Farrell previously held the position of Interim CEO. https://kalytera.co/news/kalytera-announces-robert-farrell-j-d-as-ceo-additional-board-and-management-changes/

Oct 02, 2017

Kalytera Receives IRB Approval for Proposed Phase 2 Study Evaluating CBD in the Prevention of Graft versus Host Disease

Kalytera Therapeutics, Inc. (TSXV: KALY) (OTCQB: KALTF), a clinical-stage pharmaceutical company developing cannabinoid therapeutics for Graft versus Host Disease (“GvHD”), today announced that it has received approval from the Institutional Review Board (“IRB”) at one of two clinical sites in Israel to commence a Phase 2 study to evaluate cannabidiol (“CBD”) for the prevention of GvHD. https://kalytera.co/news/first-irb-approval-phase-2-cbd-gvhd-study/

Aug 31, 2017

Kalytera Reports Second Quarter 2017 Financial Results

Kalytera Therapeutics, Inc. (TSXV: KALY) (OTCQB: KALTF), a clinical-stage pharmaceutical company developing cannabinoid therapeutics for Graft versus Host Disease (“GvHD”), today reported financial results for the quarter ended June 30, 2017. (All dollars U.S. unless otherwise noted.) https://kalytera.co/news/q2-2017-financial-results/

Aug 14, 2017

Kalytera Submits Phase 2 Study Protocol to IRBs for Cannabidiol in the Prevention of Graft versus Host Disease

Kalytera Therapeutics, Inc. (TSXV: KALY) (OTCQB: KALTF), a clinical-stage pharmaceutical company developing cannabinoid therapeutics for Graft versus Host Disease (“GvHD”), today announced that it has submitted an application to the Institutional Review Boards (“IRB”) of two clinical sites in Israel to commence a Phase 2 study to evaluate cannabidiol (“CBD”) for the prevention of GvHD. https://kalytera.co/news/irb-gvhd-phase-2-study-protocol/

Jul 22, 2017

Kalytera Announces Management Changes and Expansion of Leadership Team

Kalytera Therapeutics, Inc. (TSXV: KALY) (OTCQB: KALTF), a clinical-stage pharmaceutical company developing cannabinoid therapeutics for Graft versus Host Disease (“GvHD”), today announced that Andrew L. Salzman, M.D., who previously served as Kalytera’s Chief Executive Officer and Chief Medical Officer, and as a member of Kalytera’s Board of Directors, will be leaving the Company, effective June 21, 2017. Robert Farrell, J.D., President and CFO of Kalytera, will assume the role of interim Chief Executive Officer (“CEO”). Concurrent with Mr. Farrell’s appointment as interim CEO, the Company has expanded its senior management team with three new appointments. https://kalytera.co/news/management-changes-and-expansion-of-leadership-team/

May 31, 2017

Kalytera Reports First Quarter 2017 Financial Results

First Quarter 2017 Result Highlights

Working capital totaled $1.8 million, including cash and cash equivalents of $3.1 million, as of March 31, 2017, compared with $2.9 million and $673,000, respectively, as of December 31, 2016. https://kalytera.co/news/q1-2017-financial-results/

May 26, 2017

Kalytera Announces Changes to its Board of Directors

Kalytera Therapeutics, Inc. (TSXV: KALY) (OTCQB: KALTF), a clinical-stage pharmaceutical company developing cannabinoid therapeutics for Graft versus Host Disease (“GvHD”), today announced the appointment of Ronald P. Erickson as Interim Chairman of its Board of Directors. Kalytera also announced the resignations of Jerome B. Zeldis, M.D., Ph.D., Director, and David Stefansky, Chairman. https://kalytera.co/news/changes-to-bod/​

May 02, 2017

Kalytera Reports FY 2016 Results; Provides Corporate Update and 2017 Outlook

Kalytera Therapeutics, Inc. (TSXV: KALY) (OTCQB: KALTF), a clinical-stage biopharmaceutical company developing cannabinoid-derived therapeutics for Graft versus Host Disease (“GvHD”) and certain other disorders, today reported its Fiscal Year 2016 results and provided a corporate update and outlook for 2017. (All dollars U.S. unless otherwise noted.) https://kalytera.co/news/kalytera-reports-fy-2016-results-provides-corporate-update-and-2017-outlook/

Apr 25, 2017

Kalytera Identifies Sites for Planned GvHD Clinical Trials

Kalytera Therapeutics, Inc. (TSXV: KALY), a clinical-stage biopharmaceutical company developing next-generation cannabinoid-derived therapeutics, today announced that it has developed the multi-center location component of the plan for the proposed clinical trials to evaluate cannabidiol (“CBD”) for the prevention and treatment of Graft versus Host Disease (“GvHD”). Kalytera is developing this clinical trial plan with the intent of obtaining FDA and EMEA approval for commercialization. https://kalytera.co/news/kalytera-identifies-sites-for-planned-gvhd-clinical-trials/

Apr 17, 2017

Kalytera Applies for $5 Million R&D Grant from IIA

Kalytera Therapeutics, Inc. (TSXV: KALY), a clinical stage biopharmaceutical company developing next generation cannabinoid-derived therapeutics, today announced it has applied for a $5 million grant from the Israel Innovation Authority (“IIA”) to fund development of its portfolio of novel cannabidiol (“CBD”) prodrugs. https://kalytera.co/news/kalytera-applies-for-5-million-rd-grant-from-iia/

Mar 17, 2017

Kalytera Therapeutics Appoints Pini Ben-Elazar to Board of Directors

Kalytera Therapeutics, Inc. (TSXV: KALY) today announced that Mr. Pini Ben-Elazar has been appointed to Kalytera’s Board of Directors. In connection with Kalytera’s recent acquisition of Talent Biotechs, Ltd., the selling shareholders of Talent had the right to nominate a person to join Kalytera’s Board of Directors. The selling shareholders nominated Mr. Ben-Elazar. https://kalytera.co/news/kalytera-therapeutics-appoints-pini-ben-elazar-to-board-of-directors/

Feb 22, 2017

Kalytera Therapeutics Announces Encouraging Results of a Phase 2a Clinical Study for the Treatment of Acute Graft versus Host Disease

Kalytera Therapeutics, Inc. (TSXV: KALY) (“Kalytera”) is pleased to announce encouraging results from a Phase 2a study evaluating the safety and efficacy of cannabidiol (“CBD”), a primary constituent of the marijuana plant, for the treatment of acute (Grade 3-4) Graft versus Host Disease (“GvHD”).https://kalytera.co/news/kalytera-therapeutics-announces-encouraging-results-of-a-phase-2a-clinical-study-for-the-treatment-of-acute-graft-versus-host-disease/

Feb 16, 2017

Kalytera Therapeutics Completes Acquisition of Talent Biotechs

Kalytera Therapeutics, Inc. (TSXV:KALY) (“Kalytera”) announced today that it has successfully completed the previously announced acquisition (the “Acquisition”) of Talent Biotechs Ltd. (“Talent”), strengthening Kalytera’s position as an emerging market leader in cannabidiol (“CBD”) pharmaceuticals. Talent is a privately held, Israeli-based company evaluating the use of CBD to prevent and treat Graft versus Host Disease (“GvHD”). https://kalytera.co/news/kalytera-completes-acquisition-of-talent-biotechs/

Feb 07, 2017

Kalytera Announces Closing of First Tranche of Brokered Private Placement

Kalytera Therapeutics, Inc. (TSXV:KALY) (the “Company” or “Kalytera”) is pleased to announce a first tranche (“First Tranche”) closing of its previously announced brokered private placement offering (the “Offering”) of common shares (the “Common Shares”) of the Company. The First Tranche closing consisted of the issuance of 29,833,300 Common Shares at a price of CDN$0.45 per Common Share (the “Offering Price”) for gross proceeds of CDN$13,424,985. Clarus Securities Inc., as lead agent, together with Haywood Securities Inc. and Canaccord Genuity Corp. https://kalytera.co/news/kalytera-announces-closing-of-first-tranche-of-brokered-private-placement/

Jan 24, 2017

Kalytera Announces Revised and Upsized Private Placement Terms

What's this item about? What makes it interesting? Write a catchy description to grab your audience's attention...

Jan 18, 2017

Kalytera Announces Preliminary Results of a Phase 2a Clinical Study by Talent Biotechs in the Prevention of Graft versus Host Disease

Kalytera Therapeutics, Inc. (TSXV:KALY) (“Kalytera”) today announced preliminary results of a 12 patient Phase 2a study evaluating the safety and efficacy of prolonged use of cannabidiol (“CBD”) in the prevention of Graft versus Host Disease (“GvHD”). Preliminary results of the study demonstrate that only 15% of patients in the CBD treatment group developed Grade 2-4 GvHD, as compared to a 60-70% incidence predicted by historical data used as a control. The study was conducted by Talent Biotechs Ltd. (“Talent”), a privately held, Israeli-based developer of CBD therapeutics. https://kalytera.co/news/talent-phase-2a-study-data

Jan 17, 2017

We’ve arrived at 2017! Many of us know that being a cannabis entrepreneur means keeping up to date with the latest industry insights and trends; to know where the conversations surrounding cannabis are being held and where the dialogue will evolve next.

http://www.directcannabisnetwork.com/industry-leaders-see-cannabis-industry-going-2017

Dec 30, 2016

Kalytera Therapeutics, Inc. (formerly Santa Maria Petroleum Inc.) (the "Company") (NEX:SMQ.H) announces that, in connection with the conditional approval of the TSX Venture Exchange (the "TSXV") regarding the previously announced merger transaction (the "Transaction") with Kalytera Therapeutics, Inc. ("Kalytera") and certain other transactions related thereto, the filing statement of the Company dated December 30, 2016 (the "Filing Statement"), which describes the Transaction and certain other related transactions which have occurred or will occur prior to or in connection with, the Transaction, has been filed on SEDAR under the Company's profile at www.sedar.com. http://www.marketwired.com/press-release/kalytera-therapeutics-inc-formerly-santa-maria-petroleum-inc-announces-filing-filing-tsx-venture-smq.h-2185778.htm

Dec 27, 2016

If there’s any industry in the US that’s growing at a rate like that of the tech sector in the late ‘90s, it’s the cannabis space. 28 states now allow for the medical consumption of cannabis, eight of which allow for its use as a recreational substance, and there’s no sign that state-specific industries will slow down their rate of growth.​ https://www.equities.com/news/innovation-in-the-cannabis-industry

Dec 26, 2016

This year saw big election wins for marijuana in several states. In addition, Colorado crossed the $1 billion mark for annual marijuana sales. Now a new year is almost here and a new presidential administration for the cannabis industry to navigate. It's time to look ahead and see what's in store for the cannabis industry in 2017. http://www.forbes.com/sites/debraborchardt/2016/12/26/here-are-the-top-2017-predictions-for-the-marijuana-industry/#26e7e71f689a

Dec 20, 2016

It’s a prognosis patients never want to hear: “No successful treatment regimens have been devised.” That’s the American Migraine Foundation’s summary of an ailment known as New Daily Persistent Headache (NDPH). Since Jonathan Zaid was diagnosed with the rare condition in 2007 at age 14, he’s been prescribed more than 40 different drugs in a futile attempt to alleviate migraines so debilitating that he couldn’t concentrate or fall asleep at night. Then, in 2014, his physician shifted tactics and prescribed a surprising new medication that almost immediately improved Zaid’s quality of life — medical marijuana. http://www.ozy.com/fast-forward/the-new-wonder-drug-synthetic-cannabis/74514

Dec 14, 2016

Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, today announced the appointment of Andrew L. Salzman, M.D. as Kalytera’s Chief Executive Officer. Dr. Salzman will also serve as Chief Medical Officer and as a member of Kalytera’s Board of Directors. https://kalytera.co/andrew-salzman-chief-executive-officer/

Dec 10, 2016

Despite its continuing hardline stance against marijuana, the US Drug Enforcement Agency (DEA) has shown some signs of relenting and this summer opened the door to allowing more farms to grow cannabis for official research purposes. That’s an important step forward that may change the potential marijuana has for medical treatment. Up to this point, researchers have had to depend on just one farm at the University of Mississippi to supply cannabis for all studies. https://www.theguardian.com/lifeandstyle/2016/dec/10/medical-marijuana-research-new-treatments

Dec 09, 2016

Therakine Ltd. announces the appointment of Mr. Steven B. Bettis as its Chief Executive Officer.
Mr. Bettis, who has been working with the company as a consultant for several months, brings 25 years of commercial and drug development experience to
TheraKine, and was formerly the President and Co-founder of Eyetech Inc. http://www.releasewire.com/press-releases/therakine-announces-new-chief-executive-officer-750118.htm

Nov 04, 2016

TheraKine Ltd. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 9474715, which enables innovative methods for locally injectable sustained release formulations of biologic and small molecule drugs with high concentration and superior injectability. https://upticknewswire.com/therakine-patent-portfolio-for-sustained-release-of-injectable-drugs/

Nov 01, 2016

On November 8, constituents in nine states will vote on medical or recreational, known as adult use, marijuana laws in what could be the largest policy decision pot has faced since being outlawed by the U.S. government in 1937. In California particularly, legalizing recreational weed for adults (defined in California’s Prop. 64, the Adult Use of Marijuana Act, for people 21 years and older) will have ramifications beyond the state’s borders. That’s because California’s projected dual market of medical and recreational pot is larger than those of Colorado, Oregon, Washington and Alaska combined—the first four states to have legalized weed. http://www.playboy.com/articles/can-medical-and-recreational-weed-co-exist

Oct 21, 2016

FitLife Brands, Inc. ("FitLife") (OTCBB: FTLF), an international provider of innovative and proprietary nutritional supplements for health conscious consumers marketed under the brand names NDS Nutrition Products™ ("NDS") (www.ndsnutrition.com), PMD® (www.pmdsports.com), SirenLabs® (www.sirenlabs.com), CoreActive® (www.coreactivenutrition.com), Metis Nutrition™ (www.metisnutrition.com), iSatori™ (www.isatori.com), Energize (www.tryenergize.com), and BioGenetic Laboratories, (www.biogeneticlabs.com), today announced that Stephen Adele, CEO of iSatori and Chief Innovation Officer of FitLife Brands, has resigned from the Company. He will continue to serve on the Company's Board of Directors. http://ir.fitlifebrands.com/profiles/investor/ResLibraryView.asp?ResLibraryID=82552&GoTopage=1&Category=2139&BzID=2232&G=861

Oct 12, 2016

Invion is pleased to invite Shareholders to the Company’s 2016 Annual General Meeting. http://inviongroup.com/annual-general-meeting-notice-of-meeting-and-proxy-form/

Oct 06, 2016

Santa Maria Petroleum Inc. (the "Company") (NEX:SMQ.H) is pleased to announce that it has entered into a non-binding letter of intent dated October 6, 2016 (the "Letter of Intent") in respect of a proposed arm's length merger transaction with Kalytera Therapeutics, Inc. ("Kalytera") that would result in a reverse takeover of the Company by Kalytera (the "Proposed Transaction"), subject to approval of the TSX Venture Exchange ("TSXV") to list the shares of the resulting entity (the "Resulting Issuer") on the TSXV, among other conditions. The Resulting Issuer will operate as a life sciences issuer continuing the business of Kalyterahttp://www.marketwired.com/press-release/santa-maria-announces-letter-intent-proposed-merger-with-kalytera-therapeutics-tsx-venture-smq.h-2164748.htm

Sep 30, 2016

FitLife Brands, Inc. ("FitLife") (OTCBB: FTLF), an international provider of innovative and proprietary nutritional supplements for health conscious consumers marketed under the brand names NDS Nutrition Products™ ("NDS") (www.ndsnutrition.com), PMD® (www.pmdsports.com), SirenLabs® (www.sirenlabs.com), CoreActive® (www.coreactivenutrition.com), Metis Nutrition™ (www.metisnutrition.com), iSatori™ (www.isatori.com), Energize (www.tryenergize.com), and BioGenetic Laboratories, (www.biogeneticlabs.com), today announced results for its fiscal third quarter ended September 30, 2016. http://ir.fitlifebrands.com/profiles/investor/ResLibraryView.asp?ResLibraryID=82698&GoTopage=1&Category=2139&BzID=2232&G=861

1 / 1

Please reload